Stock PEN PENUMBRA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Penumbra, Inc.

Equities

PEN

US70975L1070

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
204.4 USD -0.53% Intraday chart for Penumbra, Inc. +0.83% -18.74%
Apr. 23 Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots CI
Apr. 17 DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,735 6,354 10,734 8,449 9,709 7,922 - -
Enterprise Value (EV) 1 5,735 6,354 10,734 8,287 9,567 7,705 7,569 7,364
P/E ratio 123 x -398 x 2,052 x -4,449 x 108 x 74.1 x 52.4 x 39.7 x
Yield - - - - - - - -
Capitalization / Revenue 10.5 x 11.3 x 14.4 x 9.97 x 9.17 x 6.36 x 5.47 x 4.72 x
EV / Revenue 10.5 x 11.3 x 14.4 x 9.78 x 9.04 x 6.19 x 5.22 x 4.39 x
EV / EBITDA 103 x 410 x 209 x 214 x 74.4 x 44.6 x 32.3 x 24.8 x
EV / FCF 1,262 x -110 x -919 x -111 x 116 x 73.2 x 59.5 x 45.9 x
FCF Yield 0.08% -0.91% -0.11% -0.9% 0.86% 1.37% 1.68% 2.18%
Price to Book 11.8 x 9.93 x 11.3 x 8.49 x 8.25 x 6.25 x 5.33 x 4.47 x
Nbr of stocks (in thousands) 34,914 36,311 37,359 37,979 38,596 38,758 - -
Reference price 2 164.3 175.0 287.3 222.5 251.5 204.4 204.4 204.4
Announcement Date 2/25/20 2/23/21 2/22/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 547.4 560.4 747.6 847.1 1,059 1,246 1,449 1,678
EBITDA 1 55.61 15.49 51.45 38.73 128.5 172.8 234.1 297.5
EBIT 1 47.51 2.595 35.04 14.41 101.3 137.8 191.4 260.1
Operating Margin 8.68% 0.46% 4.69% 1.7% 9.57% 11.06% 13.21% 15.5%
Earnings before Tax (EBT) 1 50.14 - -10.5 3.892 79.65 136.2 193.9 257.9
Net income 1 48.46 -15.7 5.284 -2.002 90.95 106.2 153.6 204.6
Net margin 8.85% -2.8% 0.71% -0.24% 8.59% 8.52% 10.6% 12.2%
EPS 2 1.340 -0.4400 0.1400 -0.0500 2.320 2.759 3.900 5.153
Free Cash Flow 1 4.543 -58 -11.68 -74.96 82.12 105.3 127.2 160.3
FCF margin 0.83% -10.35% -1.56% -8.85% 7.76% 8.45% 8.78% 9.56%
FCF Conversion (EBITDA) 8.17% - - - 63.89% 60.92% 54.36% 53.9%
FCF Conversion (Net income) 9.38% - - - 90.29% 99.16% 82.82% 78.35%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/25/20 2/23/21 2/22/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 190.1 204 203.9 208.3 213.7 221.2 241.4 261.5 270.9 284.7 275.7 301.4 323.1 344.7 319.9
EBITDA 1 12.41 8.241 3.465 5.79 14.04 13.65 16.96 26.98 40.15 44.45 25.75 36.74 53.09 57.91 46.31
EBIT 1 8.781 2.488 -2.261 1.646 7.814 7.213 10.39 20.27 33.22 37.41 16.96 28.92 42.66 48.76 38.8
Operating Margin 4.62% 1.22% -1.11% 0.79% 3.66% 3.26% 4.3% 7.75% 12.26% 13.14% 6.15% 9.6% 13.2% 14.14% 12.13%
Earnings before Tax (EBT) 1 7.782 -40.95 -5.104 -1.167 3.035 7.128 8.652 19.54 13.3 38.16 18.13 28.95 40.63 48.29 36.91
Net income 1 8.85 -24.63 0.079 -3.687 -2.271 3.877 8.562 18.96 9.214 54.22 12.26 23.17 32.04 38.22 30.36
Net margin 4.66% -12.07% 0.04% -1.77% -1.06% 1.75% 3.55% 7.25% 3.4% 19.05% 4.45% 7.69% 9.92% 11.09% 9.49%
EPS 2 0.2400 -0.6600 - -0.1000 -0.0600 0.1000 0.2200 0.4800 0.2300 1.380 0.3110 0.5866 0.8111 0.9665 0.7654
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/3/21 2/22/22 5/3/22 8/4/22 11/3/22 2/23/23 5/2/23 8/1/23 11/2/23 2/22/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - 161 142 217 353 559
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 4.54 -58 -11.7 -75 82.1 105 127 160
ROE (net income / shareholders' equity) 7.84% 0.71% 3.3% 0.65% 7.52% 8.53% 10.3% 12%
ROA (Net income/ Total Assets) 6.03% 0.54% 2.55% 0.49% 5.59% 6.48% 8.24% 9.43%
Assets 1 804 -2,929 207.5 -410.2 1,627 1,638 1,864 2,171
Book Value Per Share 2 13.90 17.60 25.40 26.20 30.50 32.70 38.30 45.70
Cash Flow per Share 2 0.7300 -0.9300 - -1.470 2.480 2.610 5.000 5.790
Capex 1 22.1 24.8 21.2 19.3 15.2 20.2 20.4 19.9
Capex / Sales 4.04% 4.42% 2.83% 2.28% 1.44% 1.62% 1.4% 1.19%
Announcement Date 2/25/20 2/23/21 2/22/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Penumbra, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
204.4 USD
Average target price
280.1 USD
Spread / Average Target
+37.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

1st Jan change Capi.
PENUMBRA, INC. Stock Penumbra, Inc.
-18.74% 7.92B
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+73.17% 12.38B
MASIMO CORPORATION Stock Masimo Corporation
+16.15% 7.2B
GETINGE AB Stock Getinge AB
+4.81% 5.84B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+5.99% 5.01B
APT MEDICAL INC. Stock APT Medical Inc.
+27.07% 4.53B
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-21.67% 3.88B
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-40.82% 2.23B
SKAN GROUP AG Stock SKAN Group AG
+1.49% 2.02B
SHENZHEN YHLO BIOTECH CO., LTD. Stock Shenzhen YHLO Biotech Co., Ltd.
+5.07% 1.88B
Medical Equipment
  1. Stock Market
  2. Equities
  3. PEN Stock
  4. Financials Penumbra, Inc.